guy jud (@jud_guy) profile picture

guy jud

@jud_guy
Joined December 2017
  • Tweets1.3K
  • Following46
  • Followers357
26Media
Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)
$NMTC Never been in a stock lose so much value in one year on so little news: -86% YTD, $7.0 m market cap, $12.0 m sales, $2.0 m cash, $500k monthly cash burn (ugh) 2 FDA approved caths. Thank goodness it's a small position but doesnt make me feel less stupid
1
1
290
I figure it's either a tax loss or a significant add once the dilution/cap raise question is answered, likely the former though as I can't get comfy w some mgmt decisions. Would love to hear views from anyone who has deep dived co. and has a opinion, neg or pos
1
1
156
$KRMD Q3 was fine and looks like we will see acceleration resume Q4. FWIW I like the new CEO and was encouraged that Rystiggo contributed. They need a oncology deal to replace Phesgo as that's a very large opportunity. Secondary immunodeficiency also another growth leg IMO
168
$DCTH obviously a Q3 blowout. I think Q4 guidance is way too conservative given new starts. Love move into ICC (8x to 10x larger than mUm) w/ good historical evidence from IHP & CHEMOSTAT; cRc interim moved to mid 27 (from late 27); Believe CHOPIN add to NCCN still in cards
2
35
1,380
$DCTH Interesting that this patient received 2 HEPZATO treatments prior to beginning KIMMTRACK facebook.com/share/r/18ohCRc…
2
1
1
14
2,357
$DCTH My Q3 Est:$29.1 m ($27.1 m US) , assumes new patient starts were 0.7 Q1, 0.5 Q2, 0.2 Q3E; 4 repeat procedures per every 6 weeks @ $175K. 31 hospitals end of Q2 and 33 end of Q3. Est YE hospital activations from go from 37 year to 35.
1
12
1,281
$DCTH Revenue Recognition Schedule: Start Quarter: 1.0 kit ($175,000) Lag 1 Quarter: 1.5 kits ($262,500) Lag 2 Quarter: 1.5 kits ($262,500)
3
454
$NMTC (1) -81% YTD, -94.9% 5Y. CEO paid $787K;CFO gets $405K; CTO $333K . For an 18 person company, given the cash burn and the historical stock performance, egregious that top management gorges while shareholders bleed.
1
2
574
$NMTC (2)Bought small position , now a tiny position due to YTD decline . Blame myself , b/c mgmt always critical in micro , but I thought (and still feel) the tech itself has potential (and co. has approved products, $10 m revs, and drug delivery potential
1
1
201
$NMTC (3) Am surprised no pressure from the board or any institutional investors to replace top management, lower cash burn (inc salaries), and close deals w partners, and if all else fails, sell the company. Looking like a tax loss at this point sadly
1
2
160
$DCTH New treatment in Nebraska targets rare melanoma that spreads from eye to liver omaha.com/news/local/busines… via @owhnews
New treatment in Nebraska targets rare melanoma that spreads from eye to liver

New treatment in Nebraska targets rare melanoma that spreads from eye to liver

Melanoma, a potentially deadly form of cancer, most often appears in the skin. But in rare cases, it starts in the eye, specifically in melanocytes, the cells that produce the

omaha.com
10
608
$DCTH $IDYA $IMCR
A Cure In Sight (@ACureInSight1) profile pictureA Cure In Sight@ACureInSight1Oct 12
🔬 Uveal melanoma is different from skin melanoma—and so are its treatment challenges. Explore insights from Dr. Marlana Orloff on emerging therapies, clinical trials, and personalized treatment decisions. 🔗 acureinsight.org/why-uveal-m…
Image from A Cure In Sight (@ACureInSight1)
4
637
$DCTH facebook.com/share/p/19jTDJL…
5
733
I confess I have AI envy. These stocks go up every day. It must be boring to make $ so easily. At what point does everything AI get priced in or is each day a new surprise ? Oddly, when I was much younger, it was mentally easier to hold my nose and buy manias (dot com- hell yea)
2
162
$CGEM event.summitcast.com/view/9n… Maybe I’m missing something , but their decision to share all the data at once makes sense to me
2
2
651
FWIW I don’t see the shift as either a tell + or - but clearly market disagrees . Would love to also know how the stock moved -20% yesterday before the PR
1
112
The link lets you listen to $CGEM’s webcast at Stifel ( held 9/24)
1
260
$DCTH I believe CHOPIN protocol gets added to NCCN this fall as the cancer treatment guidelines are updated 1x a year typically and it’s been > 6 months since CHOPIN published so been plenty of time for review of data
2
15
1,973
$DCTH looks like Nebraska Medicine just became 32nd active REMS site for HEPZATO
19
1,616
$NMTC Yesterday's PR re progress in the StereoCED neural drug delivery biz is + though surge and then plunge was puzzling. The company has very little $ but StereoCED has a real chance to succeed. Performed w/o MRI and ability to deliver drug/record data w same catheter
1
1
410
The CEO total compensation package ($1.15M) is roughly 70–75% higher than for peer companies (and versus market cap of $16.0 m) which is too high. On flip side, revs are tracking close to $10 m, zero debt. I have a small position long
1
147
Load more